PremiumCompany AnnouncementsBrainstorm Cell Therapeutics Reports Q1 2025 Financials Brainstorm Cell Therapeutics: Progress and Challenges in ALS Trial One new option listing and nine option delistings on May 19th PremiumPre-EarningsBCLI Earnings this Week: How Will it Perform? BrainStorm granted compliance extension from Nasdaq BrainStorm receives Notice of Allowance for patent on exosome technology PremiumThe FlyBiotech Alert: Searches spiking for these stocks today Brainstorm Therapeutics Advances NurOwn® Phase 3b Trials BrainStorm trading halted, news pending